Passage Bio Inc

Passage Bio pioneers AAV‑gene therapy for rare CNS disorders, blending breakthrough science with dynamic market moves—discover its potential impact and investor outlook.

Passage Bio, Inc. is a pioneering biotech company dedicated to developing innovative genetic therapies for rare monogenic central nervous system diseases, with a strong focus on AAV-delivered therapeutics and a promising future outlook.